Proteolytic release of the receptor for advanced glycation end products from in vitro and in situ alveolar epithelial cells.

Although the receptor for advanced glycation end products (RAGE) has been used as a biological marker of alveolar epithelial cell injury in clinical studies, the mechanism for release of soluble RAGE from lung epithelial cells has not been well studied. Therefore, these studies were designed to determine the mechanism for release of soluble RAGE after lipopolysaccharide (LPS) challenge. For these purposes, alveolar epithelial cells from rat lungs were cultured on Transwell inserts, and LPS was added to the apical side (500 μg/ml) for 16 h on day 7. On day 7, RAGE was expressed predominantly in surfactant protein D-negative cells, and LPS challenge induced release of RAGE into the medium. This response was partially blocked by matrix metalloproteinase (MMP) inhibitors. Transcripts of MMP-3 and MMP-13 were upregulated by LPS, whereas RAGE transcripts did not change. Proteolysis by MMP-3 and MMP-13 resulted in soluble RAGE expression in the bronchoalveolar lavage fluid in the in situ rat lung, and this reaction was inhibited by MMP inhibitors. In human studies, both MMP-3 and -13 antigen levels were significantly correlated with the level of RAGE in pulmonary edema fluid samples. These results support the conclusion that release of RAGE is primarily mediated by proteolytic damage in alveolar epithelial cells in the lung, caused by proteases in acute inflammatory conditions in the distal air spaces.

[1]  P. Reynolds,et al.  Receptors for advanced glycation end-products targeting protect against hyperoxia-induced lung injury in mice. , 2010, American journal of respiratory cell and molecular biology.

[2]  Inês Barroso,et al.  Genome-wide association study identifies five loci associated with lung function , 2010, Nature Genetics.

[3]  A. V. Pileggi,et al.  Receptor for Advanced Glycation End Products in Donor Lungs Is Associated with Primary Graft Dysfunction After Lung Transplantation , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  Carsten Ehrhardt,et al.  The Receptor for Advanced Glycation End Products (RAGE) and the Lung , 2010, Journal of biomedicine & biotechnology.

[5]  A. Hofman,et al.  Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function , 2010, Nature Genetics.

[6]  C. Deutschman,et al.  Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. , 2009, American journal of respiratory and critical care medicine.

[7]  I. Messana,et al.  Bronchoalveolar lavage fluid peptidomics suggests a possible matrix metalloproteinase-3 role in bronchopulmonary dysplasia , 2009, Intensive Care Medicine.

[8]  M. Matthay,et al.  Receptor for advanced glycation end-products (RAGE) is an indicator of direct lung injury in models of experimental lung injury. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[9]  T. Kubo,et al.  Osteoblasts derived from osteophytes produce interleukin-6, interleukin-8, and matrix metalloproteinase-13 in osteoarthritis , 2009, Journal of Bone and Mineral Metabolism.

[10]  M. Matthay,et al.  Elevated levels of the receptor for advanced glycation end products, a marker of alveolar epithelial type I cell injury, predict impaired alveolar fluid clearance in isolated perfused human lungs. , 2009, Chest.

[11]  J. D’Armiento,et al.  Blockade of receptor for advanced glycation end product attenuates pulmonary reperfusion injury in mice. , 2008, The Journal of thoracic and cardiovascular surgery.

[12]  P. Saftig,et al.  A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  P. Parsons,et al.  Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury , 2008, Thorax.

[14]  A. Carter,et al.  Identification, classification, and expression of RAGE gene splice variants , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  J. Varani,et al.  Matrix metalloproteinase-3 (stromelysin-1) in acute inflammatory tissue injury. , 2007, Experimental and molecular pathology.

[16]  M. Matthay,et al.  Acute Lung Injury Edema Fluid Decreases Net Fluid Transport across Human Alveolar Epithelial Type II Cells* , 2007, Journal of Biological Chemistry.

[17]  A. Arroliga,et al.  Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  M. Matthay,et al.  Physiological and biochemical markers of alveolar epithelial barrier dysfunction in perfused human lungs. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[19]  T. van der Poll,et al.  Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome , 2007, Critical care medicine.

[20]  Chang-Keun Lee,et al.  Advanced glycation end products increases matrix metalloproteinase‐1, ‐3, and ‐13, and TNF‐α in human osteoarthritic chondrocytes , 2007, FEBS letters.

[21]  C. Cooper,et al.  Variation in the matrix metalloproteinase‐3, ‐7, ‐12 and ‐13 genes is associated with functional status in rheumatoid arthritis , 2007, International journal of immunogenetics.

[22]  P. Parsons,et al.  Pathogenetic significance of biological markers of ventilator-associated lung injury in experimental and clinical studies. , 2006, Chest.

[23]  A. Bresnick,et al.  Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: Role of the receptor for advanced glycation end products. , 2006, Arthritis and rheumatism.

[24]  M. Matthay,et al.  Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. , 2006, American journal of respiratory and critical care medicine.

[25]  T. Standiford,et al.  Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury. , 2006, Human pathology.

[26]  H. Folkesson,et al.  Alveolar epithelial ion and fluid transport: recent progress. , 2006, American journal of respiratory cell and molecular biology.

[27]  S. Ye Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. , 2006, Cardiovascular research.

[28]  E. Rieber,et al.  Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells , 2006, Cell and Tissue Research.

[29]  A. Cole,et al.  Articular chondrocytes express the receptor for advanced glycation end products: Potential role in osteoarthritis. , 2005, Arthritis and rheumatism.

[30]  M. Matthay,et al.  Alveolar epithelium: role in lung fluid balance and acute lung injury. , 2005, Proceedings of the American Thoracic Society.

[31]  Masaki Tanaka,et al.  Contributions of high mobility group box protein in experimental and clinical acute lung injury. , 2004, American journal of respiratory and critical care medicine.

[32]  J. Enghild,et al.  Purification and Characterization of Mouse Soluble Receptor for Advanced Glycation End Products (sRAGE)* , 2004, Journal of Biological Chemistry.

[33]  M. Matthay,et al.  Fluid transport across cultured rat alveolar epithelial cells: a novel in vitro system. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[34]  N. Kohno,et al.  Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[35]  Y. Hata,et al.  Receptor for advanced glycation end‐products is a marker of type I lung alveolar cells , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[36]  P. Parsons,et al.  Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury , 2003, Thorax.

[37]  S. Takasawa,et al.  Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. , 2003, The Biochemical journal.

[38]  S. Curran,et al.  The Structure, Regulation, and Function of Human Matrix Metalloproteinase-13 , 2002, Critical reviews in biochemistry and molecular biology.

[39]  M. Matthay,et al.  Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. , 2001, American journal of respiratory and critical care medicine.

[40]  S. Weiss,et al.  Role of stromelysin 1 and gelatinase B in experimental acute lung injury. , 2001, American journal of respiratory cell and molecular biology.

[41]  M. Matthay,et al.  Alveolar epithelial fluid transport and the resolution of clinically severe hydrostatic pulmonary edema. , 1999, Journal of applied physiology.

[42]  M. Matthay,et al.  The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. , 1999, Critical care medicine.

[43]  M. d’Ortho,et al.  Role of collagenase in mediating in vitro alveolar epithelial wound repair. , 1999, Journal of cell science.

[44]  M. Müller,et al.  Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. , 1998, Cellular and molecular biology.

[45]  M. Lamy,et al.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. , 1994, American journal of respiratory and critical care medicine.

[46]  Y. Zou,et al.  Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.